Nathan H. Empie

Array ( [id] => 16963192 [patent_doc_number] => 20210214691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => Delta133P53Beta and Delta133P53Gamma Isoforms Are Biomarkers of Cancer Stem Cells [patent_app_type] => utility [patent_app_number] => 17/166004 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18278670 [patent_doc_number] => 20230094142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/796284 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18251291 [patent_doc_number] => 20230078330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => HUMAN ANTI-DENGUE ANTIBODIES AND METHODS OF USE THEREFOR [patent_app_type] => utility [patent_app_number] => 17/759479 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -88 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17183927 [patent_doc_number] => 20210330812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => TREATMENT OF RETINAL DEGENERATION USING GENE THERAPY [patent_app_type] => utility [patent_app_number] => 17/152025 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990273 [patent_doc_number] => 20210228693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES [patent_app_type] => utility [patent_app_number] => 17/151075 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17151075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870420 [patent_doc_number] => 20210163887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS [patent_app_type] => utility [patent_app_number] => 17/148278 [patent_app_country] => US [patent_app_date] => 2021-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17148278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214853 [patent_doc_number] => 20210348190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 17/145844 [patent_app_country] => US [patent_app_date] => 2021-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17145844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16825650 [patent_doc_number] => 20210140943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => NOVEL FUSIONS AND METHOD FOR DETECTING SAME [patent_app_type] => utility [patent_app_number] => 17/144776 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824693 [patent_doc_number] => 20210139986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING ODORANT RECEPTOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/139266 [patent_app_country] => US [patent_app_date] => 2020-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17139266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18110839 [patent_doc_number] => 20230003719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => MATERIALS AND METHODS FOR INFLAMMATORY MOLECULAR MARKERS [patent_app_type] => utility [patent_app_number] => 17/757201 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -198 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17757201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18170623 [patent_doc_number] => 20230037234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => ENGINEERED CELLS FOR PRODUCTION OF CANNABINOIDS AND OTHER MALONYL-CoA-DERIVED PRODUCTS [patent_app_type] => utility [patent_app_number] => 17/780421 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18164849 [patent_doc_number] => 20230031446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => SPLIT-ENZYME SYSTEM TO DETECT SPECIFIC DNA IN LIVING CELLS [patent_app_type] => utility [patent_app_number] => 17/778254 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483701 [patent_doc_number] => 20230211004 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => TETANUS TOXOID AND CRM-BASED PEPTIDES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/778211 [patent_app_country] => US [patent_app_date] => 2020-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17127668 [patent_doc_number] => 20210302437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => TRANSCRIPTOMIC BIOMARKER OF MYOCARDITIS [patent_app_type] => utility [patent_app_number] => 17/092468 [patent_app_country] => US [patent_app_date] => 2020-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17092468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824616 [patent_doc_number] => 20210139909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => SDF-1 Binding Nucleic Acids [patent_app_type] => utility [patent_app_number] => 17/092390 [patent_app_country] => US [patent_app_date] => 2020-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17092390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977961 [patent_doc_number] => 20210222198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => FURTHER IMPROVED AAV VECTORS PRODUCED IN INSECT CELLS [patent_app_type] => utility [patent_app_number] => 17/090807 [patent_app_country] => US [patent_app_date] => 2020-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16987 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17090807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688356 [patent_doc_number] => 20210070832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => ANTIGEN-SPECIFIC HELPER T-CELL RECEPTOR GENES [patent_app_type] => utility [patent_app_number] => 17/076842 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16614011 [patent_doc_number] => 20210032664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENE [patent_app_type] => utility [patent_app_number] => 17/074135 [patent_app_country] => US [patent_app_date] => 2020-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020980 [patent_doc_number] => 20220372479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => Oligonucleotide based ex vivo cell therapy [patent_app_type] => utility [patent_app_number] => 17/765170 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16886739 [patent_doc_number] => 20210172935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGIC CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/060933 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17060933 [rel_patent_id] =>[rel_patent_doc_number] =>)